Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues

被引:76
作者
Burke, Patrick J. [1 ]
Senter, Peter D. [1 ]
Meyer, David W. [1 ]
Miyamoto, Jamie B. [1 ]
Anderson, Martha [1 ]
Toki, Brian E. [1 ]
Manikumar, Govindarajan [2 ]
Wani, Mansukh C. [2 ]
Kroll, David J. [3 ]
Jeffrey, Scott C. [1 ]
机构
[1] Seattle Genet Inc, Bothell, WA 98021 USA
[2] Res Triangle Inst, Nat Prod Lab, Res Triangle Pk, NC 27709 USA
[3] N Carolina Cent Univ, BRITE, Durham, NC 27707 USA
关键词
TOPOISOMERASE-I INHIBITORS; CANCER-THERAPY; BREAST-CANCER; CURRENT PERSPECTIVES; DOXORUBICIN; PRODRUGS; BR96-DOXORUBICIN; IMMUNOCONJUGATE; RELEASE; VITRO;
D O I
10.1021/bc9001097
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Antibody-drug conjugates (ADCs) were prepared with potent camptothecin analogues attached to monoclonal antibodies (mAbs) via dipeptide or glucuronide-based linkers. Aniline-containing camptothecin analogues were employed to provide a site of linker attachment via carbamate bonds that would be stable in circulation. The camptothecin analogues, 7-butyl-10-amino-camptothecin and 7-butyl-9-amino-10,11-methylenedioxy-camptothecin, are generally 10-1000 times more potent than camptothecin. Dipeptide and glucuronide drug linkers were employed containing self-immolative spacers that release drug following lysosomal degradation upon ADC internalization into antigen-positive cell lines. The camplothecin drug linkers were conjugated to three antibodies: chimeric BR96, chimeric AC10, and humanized IF6, which bind to the Lewis-Y antigen on carcinomas, CD30 on hematologic malignancies, and CD70 present on hematologic malignancies and renal cell carcinoma, respectively. ADCs bearing the potent camptothecin analogue, 7-butyl-9-anlino-10,11-methylenedioxy-camptothecin, were highly potent and immunologically specific on a panel of cancer cell lines in vitro, and efficacious at well-tolerated doses in a renal cell carcinoma xenograft model.
引用
收藏
页码:1242 / 1250
页数:9
相关论文
共 37 条
[1]   Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex [J].
Adams, DJ ;
da Silva, MW ;
Flowers, JL ;
Kohlhagen, G ;
Pommier, Y ;
Colvin, OM ;
Manikumar, G ;
Wani, MC .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :135-144
[2]  
BEERAM M, 2007, J CLIN ONCOL, V25
[3]   Antibody-drug conjugates for cancer therapy [J].
Carter, Paul J. ;
Senter, Peter D. .
CANCER JOURNAL, 2008, 14 (03) :154-169
[4]   Targeted cancer therapy: Conferring specificity to cytotoxic drugs [J].
Chari, Ravi V. J. .
ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (01) :98-107
[5]   Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin [J].
de Groot, FMH ;
Busscher, GF ;
Aben, RWM ;
Scheeren, HW .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (17) :2371-2376
[6]   Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release [J].
de Groot, FMH ;
Loos, WJ ;
Koekkoek, R ;
van Berkom, LWA ;
Busscher, GF ;
Seelen, AE ;
Albrecht, C ;
de Bruijn, P ;
Scheeren, HW .
JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (26) :8815-8830
[7]   Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J].
Doronina, SO ;
Toki, BE ;
Torgov, MY ;
Mendelsohn, BA ;
Cerveny, CG ;
Chace, DF ;
DeBlanc, RL ;
Gearing, RP ;
Bovee, TD ;
Siegall, CB ;
Francisco, JA ;
Wahl, AF ;
Meyer, DL ;
Senter, PD .
NATURE BIOTECHNOLOGY, 2003, 21 (07) :778-784
[8]   Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity [J].
Dubowchik, GM ;
Firestone, RA ;
Padilla, L ;
Willner, D ;
Hofstead, SJ ;
Mosure, K ;
Knipe, JO ;
Lasch, SJ ;
Trail, PA .
BIOCONJUGATE CHEMISTRY, 2002, 13 (04) :855-869
[9]   Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin [J].
Dubowchik, GM ;
Firestone, RA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) :3341-3346
[10]   cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J].
Francisco, JA ;
Cerveny, CG ;
Meyer, DL ;
Mixan, BJ ;
Klussman, K ;
Chace, DF ;
Rejniak, SX ;
Gordon, KA ;
DeBlanc, R ;
Toki, BE ;
Law, CL ;
Doronina, SO ;
Siegall, CB ;
Senter, PD ;
Wahl, AF .
BLOOD, 2003, 102 (04) :1458-1465